Final results from a landmark study looking at the use of GSK's Mosquirix malaria vaccine alongside antimalarial drugs and other measures have shown a 90%-plus reduction in cases. The study in ...

6.5 months after 3rd dose First episode of parasitemia >0 parasites/μL (Cohort 2) 45.0% (31.4 to 55.9); n = 367 NR Several episodes of fever and parasitemia >2500 parasites/μL (Cohort 1) 27.4% ...

Cameroon will use the first of two recently approved malaria vaccines, known as Mosquirix. The World Health Organization endorsed the vaccine two years ago, acknowledging that that even though it ...